Humanwell Healthcare ST人福
28 significant filings since 30 May 2026: 21 on share issue, 3 on acquisition or disposal and 1 on dividend, and 1 other kind. The latest, on 24 Sep 2026: 中信证券股份有限公司、招商证券股份有限公司关于人福医药集团股份公司向特定对象发行A股股票之发行保荐书.
自 30 May 2026 起有 28 份重大公告：share issue 21 份、acquisition or disposal 3 份、dividend 1 份，另有 1 类。最新一份（24 Sep 2026）：中信证券股份有限公司、招商证券股份有限公司关于人福医药集团股份公司向特定对象发行A股股票之发行保荐书。
The tick on each bar marks the whole market, where 99.3% of rated reports in the same twelve months said Buy or Outperform. 刻度线为全市场水平：同期 99.3% 的评级为买入或跑赢。 Every rated report on this company said Buy or Outperform.
| Date 日期 | Broker 券商 | Analyst 分析师 | From 原评级 | To 新评级 | |
|---|---|---|---|---|---|
| 15 Nov 2023 | 西南证券 | 杜向阳 | Buy 买入 | ▼ | Outperform 增持 |
Each broker's rating is compared with its previous report. 每家券商的评级与其上一份研报比较。
| Broker 券商 | Analyst 分析师 | Latest Rating 最新评级 | Date 日期 | Reports 研报 | Target 目标价 |
|---|---|---|---|---|---|
| 太平洋 | 谭紫媚,张懿 | Buy 买入 | 5 Nov 2025 | 1 | — |
Each row is a broker's latest report in the last twelve months. A price target is given in 0 of 1 report. 每行为该券商近十二个月的最新研报；1 份中 0 份给出目标价。
Each bar counts the brokers publishing on this company in a quarter. The latest quarter is not yet complete. 每根柱为该季度发布本公司研报的券商数，最近一个季度尚未结束。